Genetic link between cancer and thrombosis

Carla Boccaccio, Paolo M. Comoglio

Research output: Contribution to journalArticle

Abstract

From the beginning of their lives, cancer cells exert a procoagulant activity in their microenvironment, which can extend systemically and become clinically evident as Trousseau's syndrome, the well-known association between tumor and thrombosis. It is becoming clear that the genetic mechanisms responsible for neoplastic transformation (activation of oncogenes such as RAS or MET, and inactivation of tumor suppressor genes such as p53 or PTEN) directly induce the expression of genes controlling hemostasis. Activation of blood coagulation results in a selective advantage for cancer cells, as fibrin provides a scaffold for anchorage and invasion, and coagulation proteins induce receptor-mediated intracellular signals promoting invasive growth. Targeting the tumor procoagulant activity can fight not only a dangerous tumor adverse effect, but also the core mechanisms of cancer onset and progression.

Original languageEnglish
Pages (from-to)4827-4833
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number29
DOIs
Publication statusPublished - Oct 10 2009

Fingerprint

Thrombosis
Neoplasms
Blood Coagulation
Hemostasis
Tumor Suppressor Genes
Fibrin
Oncogenes
Gene Expression
Growth
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Genetic link between cancer and thrombosis. / Boccaccio, Carla; Comoglio, Paolo M.

In: Journal of Clinical Oncology, Vol. 27, No. 29, 10.10.2009, p. 4827-4833.

Research output: Contribution to journalArticle

Boccaccio, Carla ; Comoglio, Paolo M. / Genetic link between cancer and thrombosis. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 29. pp. 4827-4833.
@article{23119a05ab3249499a006ce945c50c2f,
title = "Genetic link between cancer and thrombosis",
abstract = "From the beginning of their lives, cancer cells exert a procoagulant activity in their microenvironment, which can extend systemically and become clinically evident as Trousseau's syndrome, the well-known association between tumor and thrombosis. It is becoming clear that the genetic mechanisms responsible for neoplastic transformation (activation of oncogenes such as RAS or MET, and inactivation of tumor suppressor genes such as p53 or PTEN) directly induce the expression of genes controlling hemostasis. Activation of blood coagulation results in a selective advantage for cancer cells, as fibrin provides a scaffold for anchorage and invasion, and coagulation proteins induce receptor-mediated intracellular signals promoting invasive growth. Targeting the tumor procoagulant activity can fight not only a dangerous tumor adverse effect, but also the core mechanisms of cancer onset and progression.",
author = "Carla Boccaccio and Comoglio, {Paolo M.}",
year = "2009",
month = "10",
day = "10",
doi = "10.1200/JCO.2009.22.7199",
language = "English",
volume = "27",
pages = "4827--4833",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "29",

}

TY - JOUR

T1 - Genetic link between cancer and thrombosis

AU - Boccaccio, Carla

AU - Comoglio, Paolo M.

PY - 2009/10/10

Y1 - 2009/10/10

N2 - From the beginning of their lives, cancer cells exert a procoagulant activity in their microenvironment, which can extend systemically and become clinically evident as Trousseau's syndrome, the well-known association between tumor and thrombosis. It is becoming clear that the genetic mechanisms responsible for neoplastic transformation (activation of oncogenes such as RAS or MET, and inactivation of tumor suppressor genes such as p53 or PTEN) directly induce the expression of genes controlling hemostasis. Activation of blood coagulation results in a selective advantage for cancer cells, as fibrin provides a scaffold for anchorage and invasion, and coagulation proteins induce receptor-mediated intracellular signals promoting invasive growth. Targeting the tumor procoagulant activity can fight not only a dangerous tumor adverse effect, but also the core mechanisms of cancer onset and progression.

AB - From the beginning of their lives, cancer cells exert a procoagulant activity in their microenvironment, which can extend systemically and become clinically evident as Trousseau's syndrome, the well-known association between tumor and thrombosis. It is becoming clear that the genetic mechanisms responsible for neoplastic transformation (activation of oncogenes such as RAS or MET, and inactivation of tumor suppressor genes such as p53 or PTEN) directly induce the expression of genes controlling hemostasis. Activation of blood coagulation results in a selective advantage for cancer cells, as fibrin provides a scaffold for anchorage and invasion, and coagulation proteins induce receptor-mediated intracellular signals promoting invasive growth. Targeting the tumor procoagulant activity can fight not only a dangerous tumor adverse effect, but also the core mechanisms of cancer onset and progression.

UR - http://www.scopus.com/inward/record.url?scp=70350731332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350731332&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.22.7199

DO - 10.1200/JCO.2009.22.7199

M3 - Article

C2 - 19738115

AN - SCOPUS:70350731332

VL - 27

SP - 4827

EP - 4833

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 29

ER -